Literature DB >> 20885105

Standard therapy for glioblastoma--a review of where we are.

Ryo Nishikawa1.   

Abstract

Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat. The current standard therapy includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide. However, recurrence is quite common, so we continue to search for more effective treatments both for initial therapy and at the time of recurrence. This article will review the current standard of care and recent advances in therapy for newly-diagnosed and recurrent glioblastomas, based on the most authoritative guidelines, the National Cancer Institute's comprehensive cancer database Physician Data Query (PDQ®), and the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology(TM) for central nervous system cancers (V.1.2010), to elucidate the current position and in what direction we are advancing.

Entities:  

Mesh:

Year:  2010        PMID: 20885105     DOI: 10.2176/nmc.50.713

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  26 in total

1.  All-trans retinoic acid inhibits migration, invasion and proliferation, and promotes apoptosis in glioma cells in vitro.

Authors:  Chen Liang; Ling Yang; Shiwen Guo
Journal:  Oncol Lett       Date:  2015-04-15       Impact factor: 2.967

2.  Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.

Authors:  Annelise Letourneur; Simon Roussel; Myriam Bernaudin; Fabien Fillesoye; Jérôme Toutain; Eric T MacKenzie; Edwige Petit; Omar Touzani; Samuel Valable
Journal:  Hypertens Res       Date:  2015-06-18       Impact factor: 3.872

3.  Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.

Authors:  Kai Tang; Qiang Jin; Wei Yan; Wei Zhang; Gan You; Yanwei Liu; Tao Jiang
Journal:  Med Oncol       Date:  2011-03-11       Impact factor: 3.064

4.  A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.

Authors:  Michele Cecchi; Monica Vaiani; Marco Ceroti; Roberto Banfi
Journal:  Int J Clin Pharm       Date:  2013-03-28

5.  The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.

Authors:  Kui Zhang; Xiao-qin Wang; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

6.  MRI during radiotherapy of glioblastoma : Does MRI allow for prognostic stratification?

Authors:  C Leitzen; T Wilhelm-Buchstab; L C Schmeel; S Garbe; S Greschus; T Müdder; S Oberste-Beulmann; B Simon; H H Schild; H Schüller
Journal:  Strahlenther Onkol       Date:  2016-06-03       Impact factor: 3.621

7.  Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy.

Authors:  Junwei Zhu; Jun Su
Journal:  Indian J Microbiol       Date:  2021-07-03       Impact factor: 2.461

8.  In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.

Authors:  J L Gori; B C Beard; C Ironside; G Karponi; H-P Kiem
Journal:  Cancer Gene Ther       Date:  2012-05-25       Impact factor: 5.987

9.  Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas.

Authors:  Ming-Fu Chiang; Pei-Yi Chou; Wan-Jen Wang; Chun-I Sze; Nan-Shan Chang
Journal:  Front Oncol       Date:  2013-03-04       Impact factor: 6.244

10.  From patient-specific mathematical neuro-oncology to precision medicine.

Authors:  A L Baldock; R C Rockne; A D Boone; M L Neal; A Hawkins-Daarud; D M Corwin; C A Bridge; L A Guyman; A D Trister; M M Mrugala; J K Rockhill; K R Swanson
Journal:  Front Oncol       Date:  2013-04-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.